## AMENDMENTS TO AND LISTING OF CLAIMS

- 1-7 (Canceled)
- 8. (Currently amended) A pharmaceutical composition comprising a compound of formula I A of Claim 4 13, in free form or in a pharmaceutically\_acceptable salt form, in association with a pharmaceutically\_acceptable diluent or carrier therefor.
- 9. (Canceled)
- 10. (Currently amended) A method for preventing or treating acute or chronic transplant rejection in a subject in need of such treatment, which method comprises administering to said subject an effective amount of a compound of formula  $\frac{1}{4}$  according to Claim  $\frac{1}{4}$  or a pharmaceutically-acceptable salt thereof.
- 11. (Currently amended) A method for preventing or treating acute or chronic transplant rejection, pseriasis, or uveitis, in a subject in need of such treatment, which method comprises administering to said subject an effective amount of a compound of formula 1 of according to Claim 1 12 or a pharmacoutically\_acceptable salt thereof.
- 12. (Currently amended) A compound according to Claim 4 <u>13</u> that is 3-(1H-indol-3-yl)-4-[6-(4-methyl-piperazin-1-yl)-3-trifluoromethyl-pyridin-2-yl]-pyrrole-2,5-dione, or a pharmaceutically-acceptable salt thereof.
- 13. (Currently amended) A compound of formula I according to Claim 1, selected from the compounds of formula A:

wherein the substituents for each compound thereof have the following values:

Compoun	Ra	R₀	R <sub>2</sub>	R <sub>5</sub>	R <sub>6</sub>	R <sub>7</sub>
d						
1	Н	CH <sub>3</sub>	CF <sub>3</sub>	CH₃	Н	Н
2	H	CI	CF₃	CH <sub>3</sub>	Ħ	Ħ
3	Ħ	Ħ	CF₃	H	-CH <sub>2</sub> -CH <sub>2</sub> -	
4 <u>2</u> 5	H	CH <sub>3</sub>	CF <sub>3</sub>	Н	-CH <sub>2</sub> -CH <sub>2</sub> -	
5	Ħ	CH <sub>2</sub> - CH <sub>3</sub>	<del>CF</del> ₃	Ħ	-CH <sub>2</sub> -CH <sub>2</sub> -	
<u>63</u>	Н	CH <sub>3</sub>	F	CH₃	Н	Н
74	Н	Н	F	CH <sub>3</sub>	Н	Н
8	Ħ	CH <sub>2</sub> - CH <sub>3</sub>	F	CH <sub>3</sub>	Ħ	Ħ
<del>9</del> <u>5</u>	Н	Н	CI	CH <sub>3</sub>	Н	Н
<del>10</del>	Ħ	CH <sub>2</sub> - CH₃	CI	CH₃	Ħ	Ħ
<del>11</del> <u>6</u>	Н	CH <sub>3</sub>	CI	CH₃	Н	Н
<del>12</del>	CH₃	Ħ	F	CH₃	Ħ	Ħ
<del>13</del>	H	CI	F	CH₃	Ħ	Ħ
14	Ħ	CH₃	Ħ	CH <sub>3</sub>	Ħ	Ħ
<del>15</del>	Ħ	Ħ	Ħ	CH₃	Ħ	Ħ
<del>16</del>	H	CH₃	CH₃	CH <sub>3</sub>	Ħ	Ħ
<del>17</del>	H	Ħ	CH₃	CH <sub>3</sub>	Ħ	Ħ
<del>18</del>	CH₃	Ħ	CH₃	CH₃	Ħ	Ħ
<del>19</del> <u>7</u>	Н	CH <sub>3</sub>	NO <sub>2</sub>	CH <sub>3</sub>	Н	Н
<del>20</del>	CH <sub>3</sub>	Ħ	NO <sub>2</sub>	CH₃	H	H
<del>21</del> <u>8</u>	Н	Н	NO <sub>2</sub>	CH₃	Н	Н
<del>22</del>	CH₃	Ħ	NH <sub>2</sub>	CH₃	H	Ħ
<del>23</del>	H	CH <sub>3</sub>	NH <sub>2</sub>	CH₃	Ħ	Ħ
<del>2</del> 4	H	Ħ	NH <sub>2</sub>	CH <sub>3</sub>	H	Ħ
<del>25</del>	Ħ	Ħ	CN	CH <sub>3</sub>	Ħ	Ħ
<del>26</del>	Ħ	<del>CH</del> ₃	CN	CH₃	Ħ	Ħ
<del>27</del>	<del>CH</del> ₃	Ħ	CN	CH₃	Ħ	Ħ

or a salt thereof.

- 14. (Previously provided) A compound according to Claim 13, wherein  $R_a$  is H,  $R_b$  is H,  $R_2$  is F,  $R_5$  is CH<sub>3</sub>,  $R_6$  is H and  $R_7$  is H; or  $R_a$  is H,  $R_b$  is H,  $R_b$  is H,  $R_b$  is H,  $R_b$  is H and  $R_7$  is H.
- 15. (New) A pharmaceutical composition comprising a compound according to Claim 12, in free form or in a pharmaceutically-acceptable salt form, in association with a pharmaceutically-acceptable diluent or carrier therefor.
- 16. (New) A method for preventing or treating T-cell-mediated inflammatory or autoimmune diseases in a subject in need of such treatment, which method comprises administering to said subject a therapeutically-effective amount of a compound of formula A according to Claim 13, or a pharmaceutically-acceptable salt thereof.
- 17. (New) A method for preventing or treating T-cell-mediated inflammatory or autoimmune diseases in a subject in need of such treatment, which method comprises administering to said subject a therapeutically-effective amount of a compound according to Claim 12.